{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:41:51Z","timestamp":1761154911367,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.clinthera.2006.03.007","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T17:13:22Z","timestamp":1149700402000},"page":"340-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years"],"prefix":"10.1016","volume":"28","author":[{"given":"Jay L.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Aisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George H.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.03.007_bib1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update","volume":"43","author":"American College of Rheumatology Subcommittee on Osteoarthritis Guidelines","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.03.007_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 Update","volume":"46","author":"American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.03.007_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2036.2003.01650.x","article-title":"A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects","volume":"18","author":"Goldstein","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.007_bib4","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal anti inflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.03.007_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00045391-200007020-00008","article-title":"Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System","volume":"7","author":"Singh","year":"2000","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2006.03.007_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1572-0241.2002.05265.x","article-title":"Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects","volume":"97","author":"Stoltz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1023\/A:1018832902287","article-title":"Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding","volume":"42","author":"Wilcox","year":"1997","journal-title":"Dig Dis Sci"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2006.03.007_bib8","first-page":"A118","article-title":"Valdecoxib, a COX-2 specific inhibitor, is associated with a lower rate of endoscopic gastroduodenal ulcers than naproxen in healthy subjects (aged65\u201375 y)","volume":"53","author":"Goldstein","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2006.03.007_bib9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebocontrolled trialsin osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.03.007_bib10","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.03.007_bib11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointesti nal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.03.007_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/gast.2002.36013","article-title":"Stratifying the risk of NSAID-related upper gastrointestinal clini cal events: Results of a double-blind outcomes study in patients with rheumatoidarthritis","volume":"123","author":"Laine","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2006.03.007_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with na proxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reductionin ulcer complications: Randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.03.007_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointes tinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: Arandomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.03.007_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study","volume":"119","author":"Singh","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2006.03.007_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. Arandomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2006.03.007_bib17","first-page":"8","article-title":"NSAID induced gastrointestinal complications: The ARAMIS perspective\u20141997. Arthritis, Rheumatism, and Aging Medical Information System","volume":"51","author":"Singh","year":"1998","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.clinthera.2006.03.007_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V","article-title":"Basic biology and clinical application of specific cyclooxygenase-2 inhibitors","volume":"43","author":"Crofford","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.03.007_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1126\/science.6254151","article-title":"Prostaglandins, arachidonic acid, and inflammation","volume":"210","author":"Kuehl","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2006.03.007_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/41.9.1008","article-title":"Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen","volume":"41","author":"Bensen","year":"2002","journal-title":"Rheumatology, (Oxford)"},{"key":"10.1016\/j.clinthera.2006.03.007_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/joca.2001.0510","article-title":"Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, doubleblind,placebo-controlled comparison with naproxen","volume":"10","author":"Makarowski","year":"2002","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.clinthera.2006.03.007_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/030097401750065265","article-title":"Celecoxib versus diclofenac in the management of osteoarthritis of the knee","volume":"30","author":"McKenna","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/147323000102900602","article-title":"Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip","volume":"29","author":"Kivitz","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clinthera.2006.03.007_bib24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in longterm management of rheumatoid arthritis: Randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.03.007_bib25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2036.2004.02118.x","article-title":"Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib","volume":"20","author":"Goldstein","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.007_bib27","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0149-2918(01)80117-X","article-title":"Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo","volume":"23","author":"Harris","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.03.007_bib28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2006.03.007_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/rheumatology\/keg359","article-title":"Valdecoxib is as effective as diclofenac in the management of rheu matoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a26-week trial","volume":"42","author":"Pavelka","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2006.03.007_bib30","first-page":"530","article-title":"Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz","year":"2002","journal-title":"J Fam Pract"},{"year":"2005","series-title":"Analysis and recommendations for agency action regarding non-steroidal anti inflammatory drugs and cardiovascular risk","author":"Jenkins","key":"10.1016\/j.clinthera.2006.03.007_bib31"},{"year":"2005","series-title":"International Conference on Harmonisation. Guideline for good clinical practice","key":"10.1016\/j.clinthera.2006.03.007_bib32"},{"key":"10.1016\/j.clinthera.2006.03.007_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1572-0241.2002.05419.x","article-title":"Reliability, validity, and responsiveness of Severity of Dys pepsia Assessment (SODA) in a randomized clinical trial of a COX-2-specifiic inhibitorand traditional NSAID therapy","volume":"97","author":"Rabeneck","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0895-4356(00)00365-6","article-title":"SODA (Severity of Dyspepsia Assessment): A new effective outcome measure for dyspepsia-related health","volume":"54","author":"Rabeneck","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2036.2005.02383.x","article-title":"Meta-analysis: Upper gastrointestinal tolerability of valde coxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis","volume":"21","author":"Eisen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.007_bib36","first-page":"128","article-title":"Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients","volume":"44","author":"Agrawal","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2006.03.007_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1542-3565(04)00057-6","article-title":"A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury","volume":"2","author":"Scheiman","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib38","first-page":"1804","article-title":"Gastroduodenal safety and tolerability of lumiracox ib compared with Ibuprofen and celecoxib in patients with osteoarthritis","volume":"31","author":"Hawkey","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2006.03.007_bib39","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1572-0241.2003.07598.x","article-title":"The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events","volume":"98","author":"Hunt","year":"2003","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:27Z","timestamp":1758962847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0149291806000725"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.03.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}